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Background: The conventional dose rate of radiation therapy is 0.01–0.05 Gy per
second. According to preclinical studies, an increased dose rate may offer similar anti-
tumoral effect while dramatically improving normal tissue protection. This study aims at
evaluating the early toxicities for patients irradiated with high dose rate pulsed proton
therapy (PT).
Materials and Methods: A single institution retrospective chart review was performed
for patients treated with high dose rate (10 Gy per second) pulsed proton therapy, from
September 2016 to April 2020. This included both benign and malignant tumors with ≥3
months follow-up, evaluated for acute (≤2 months) and subacute (>2 months) toxicity after
the completion of PT.
Results: There were 127 patients identified, with a median follow up of 14.8 months (3–42.9
months). The median age was 55 years (1.6–89). The cohort most commonly consisted of
benign disease (55.1%), cranial targets (95.1%), and were treated with surgery prior to PT
(56.7%). There was amedian total PT dose of 56 Gy (30–74 Gy), dose per fraction of 2 Gy (1–
3 Gy), and CTV size of 47.6 ml (5.6–2,106.1 ml). Maximum acute grade ≥2 toxicity were
observed in 49 (38.6%) patients, of which 8 (6.3%) experienced grade 3 toxicity. No acute
grade 4 or 5 toxicity was observed. Maximum subacute grade 2, 3, and 4 toxicity were
discovered in 25 (19.7%), 12 (9.4%), and 1 (0.8%) patient(s), respectively.January 2021 | Volume 10 | Article 6130891
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Frontiers in Oncology | www.frontiersin.orgConclusion: In this cohort, utilizing high dose rate proton therapy (10 Gy per second) did
not result in a major decrease in acute and subacute toxicity. Longer follow-up and
comparative studies with conventional dose rate are required to evaluate whether this
approach offers a toxicity benefit.Keywords: high dose rate, proton therapy, cancer, early, subacute, toxicityINTRODUCTION
Proton Therapy (PT) is a particle therapy that utilizes a
Bragg Peak to reduce the radiation dose received by healthy
tissue, as demonstrated by previous in silico studies (1). PT is
preferred in patients with a long-life expectancy, to mitigate the
risk of late sequela (e.g., secondary malignancy, cardiovascular
complications, etc.) or in patients where the ideal dose
is difficult to achieve without a significant toxicity risk.
Several studies have demonstrated a clinical advantage of PT
over conventional photon radiotherapy (2–6), with many
prospective clinical trials ongoing.
To further improve the therapeutic ratio, several preclinical
studies identified a considerable biological advantage to
delivering radiation dose rate higher than the conventional
0.01 to 0.05 Gy/second. “FLASH” radiotherapy, or dose rates
exceeding 10 Gy per 100 ms, significantly reduced the radiation
damage to healthy cells/tissue without a decline in anti-tumoral
effect (7–9). This was initially demonstrated with electrons (7–9),
but subsequently with photons (10) and protons (11–13). There
is a scarcity of clinical data utilizing FLASH radiotherapy, with
only 1 case report to date, which showed that electron FLASH
reirradiation may mitigate toxicity and allow radiation delivery
even if the theoretical cumulative doses to healthy tissue would
be exceeded (14).
A recent clinical device (Proteus One©, Ion Beam
Application) was designed to deliver pencil-beam scanning
with pulsed proton at high dose rate, approximately 200–1,000
times faster than the classical dose rate (125 million protons per
pulse leading to approximately 10 Gy/s per spot, depending on
the range and energy needed) (15). Toxicity with this dose rate
level per spot has not yet been reported.
The purpose of the current study is to analyze the early
toxicities for tumors treated pencil-beam scanning with pulsed
high dose rate protons.MATERIALS AND METHODS
Patient Selection
With institutional review board approval, we retrospectively
analyzed patients receiving PT at our institution betweenhy; CTCAE, Common Terminology
al target volume; GTV, gross tumor
therapy; LC, local control; LGG, low
ging; PBS, Pencil Beam Scanning; PFS,
erapy; PTV, planning target volume;
2
September 2016 and April 2020. This study included patients
that were treated for a benign or malignant tumor, had at least 3
months of clinical follow-up, and received radiation with only PT
(without a photon component). Reirradiation was included,
defined as an overlap in the previous field with the current
GTV. Patients addressed from other centres were not included
because of the lack of updated follow-up.Follow-Up
Patients were followed weekly during PT or more frequently if
necessary. A 1-month clinical follow-up was performed after the
completion of PT. Benign tumors underwent magnetic
resonance imaging (MRI) and clinical follow-up 4 months
after completing PT and every 6 months thereafter. Malignant
tumors underwent imaging according to the standard of care for
that malignancy, which included an MRI of the irradiated region
and clinical follow-up every 4 months for 2 years, then every 6
months for 3 years, and a computed tomography (CT) scan of
the thorax and abdomen if required (e.g., head and neck cancer,
sarcomas, etc.).
Tumor response was evaluated according to RECIST (response
criteria in solid tumors) 1.1 criteria (16) and toxicities according to
the fifth version of the Common Terminology Criteria for Adverse
Events (CTCAE). Toxicity was considered “acute” if occurred
during PT or within 2 months of completing PT, and “subacute”
if occurred >2 months after completing PT. Late toxicity was not
reported due to short follow-up.Proton Therapy
PT was delivered with Pencil Beam Scanning (PBS), utilizing
the Proteus One© device (Ion Beam Application©), which is a
synchrocyclotron with active pencil beam scanning and pulsed
beam PT. Approximately 125 million protons are delivered per
pulse/spot with an energy of 100 to 226 MeV as a function of
the target depth. The dose rate per spot is approximately 10 Gy
per second, depending on the energy. The characterization of
this beam was previously reported by Rossomme et al (15).
PT immobilization was performed with a thermoplastic
mask for head and neck targets or vacuum body cast for
extracranial targets.
The dosimetry was performed using the Raystation treatment
planning system © version 6.0 before June 2019 and version 8.0
after June 2019 (Raysearch Laboratories, Stockholm, Sweden).
Dose constraints from Feuvret et al (17). and by Marks et al (18).
were used for head/neck and extracranial targets, respectively. A
relative biologic effectiveness factor for protons of 1.1 was
incorporated. PBS plans were calculated using robustJanuary 2021 | Volume 10 | Article 613089
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uncertainties, for cranial target and 3%–5 mm for extracranial
target). Robustness was applied for CTV, brain stem, spinal cord,
optic nerves, optic chiasm, femoral head, and digestive tract.
Statistical Analysis
Tumor response was defined by progression, stabilization, partial
response, or complete response. Time-to-event outcomes were
estimated from the date of last PT fraction to an event or
censored at last follow up. This included local control (LC),
and progression-free survival (PFS). LC and PFS were evaluated
via Kaplan-Meier method with a 95% confidence interval (IC
95%). Median follow-up was evaluated by the Schemper method.
All statistical analyses were performed using Statistical Package
for the Social Sciences (SPSS) version 16.0 on Windows®.RESULTS
Characteristics of Patients and
Treatments
Characteristics of patients and treatments are described inTable 1.
A total of 127 patients were included. This cohort most commonly
consisted of benign disease (55.1%), head and neck location
(95.1%), and ECOG ≤ 1 (95.8%). Majority of patients had
treatments prior to PT, which included surgery (56.7%),
chemotherapy (26%), and previous radiotherapy to the same
location (14.2%). Two patients were irradiated with a
bifractionated schedule because of previous radiation.
The most common diseases in this study include:
meningioma (10.4%), followed by malignant paranasal and
nasal sinus tumors (4.3%), and low-grade gliomas (4%).
Chemotherapy was also delivered concomitantly with PT
(10.2%) and adjuvant after PT (11%). Concomitant
chemotherapy was used for Ewing sarcoma (n=3, vincristine,
doxorubicin, ifosfamide), rhabdomyosarcoma (n=6, ifosfamide,
vincristine), malignant sinus tumor (n=3, platinum-based
chemotherapy), and metastatic lymph node from a vulvar
squamous cell carcinoma (n=1, platinum-based chemotherapy).
After PT, 1 patient underwent surgical resection.
Among patients with meningioma, malignant sinus tumor
and low-grade gliomas, the median total PT dose delivered was
56 Gy (54–60), 68.2 Gy (45–70.4), and 55.8 Gy (54–60), with a
median dose per fraction of 2 Gy (1.8–2), 2 Gy (1.8–3), and 2 Gy
(1.8–2), and a median CTV size of 41.4 ml (6.7–250.9), 88.2 ml
(22.1–572.8), and 65.5 ml (6.2–422.1), respectively.
Among patients with pelvic (n=14) or paraspinal tumors
(n=2) the median total PT dose was 65.1 Gy (50.4–73.5), with
a median dose per fraction of 2 Gy (1.8–2.4), and a median low
risk and high risk CTV size of 437.4 ml (83.2–2,106) and
112.5 ml (14.5–560.9), respectively.
Median follow-up was 14.8 months (3;-42.9). Locally, 5
(3.9%) patients experienced a complete response, 31 (24.4%) a
partial response, 71 (55.9%) stabile disease, 5 (3.9%) progressive
disease (PD), and 17 (11.9%) did not relapse after combine
combination of surgery and PT (local control). The 1-year localFrontiers in Oncology | www.frontiersin.org 3TABLE 1 | Patient and treatment characteristics.
Variable










Pituitary adenoma 7 (5.5%)
Primary orbitary tumors (lymphoma) 2 (1.6%)
Benign vascular tumor 3 (2.4%)
Malignant brain tumors
Ependymoma 4 (3.2%)




Giant cell tumor 1 (0.7%)
Ewing sarcoma 3 (2.4%)
Malignant head and neck tumors
Malignant paranasal and nasal sinus tumors 14 (11%)





Merckel carcinoma 1 (0.7%)
Isolated/local relapse of other cancer* 3 (2.4%)
Tumor location






















Median residual tumor volume 12.5 ml (0–672)
Median low-risk CTV 47.6 ml (5.6–2106.1)
Median high-risk CTV (if boost, n=46) 35.3 ml (4.1–560.9)
Median dose per fraction 2 Gy (1–3)
Median number of fractions 30 (12–60)
Median total dose 56 Gy (30–74)
Median PT duration 48 days (18–82)
Bifractionated 2 (1.6%)January 2021 | Volume*Rectal cancer, vaginal squamous cell carcinoma, clear cell carcinoma of the kidney.
**Eastern Cooperative Oncology Group.10 | Article 613089
Doyen et al. High Dose Rate Proton Therapycontrol and progression-free survival were 89.2% and
85%, respectively.
Acute Toxicities
Acute toxicities are defined as side-effects that occur during PT
or within 2 months of completing PT (Table 2). Maximum acute
toxicity grade was 0, 1, 2, and 3 for 20 (15.7%), 58 (45.7%), 41
(32.3%), and 8 (6.3%) patients, respectively. There were no grade
4 or 5 acute toxicities.
The most frequent acute toxicity was alopecia (n=40),
primarily in targets close to skin or eyelids (88 patients).
Figure 1A describes an example of alopecia occurring during
PT in a patient treated for meningioma (Patient 1). The second
most frequent acute toxicity was radiation dermatitis (n=39),
which occurred when irradiating close to the skin surface. An
example is a vertex angiosarcoma patient treated to 66 Gy (2 Gy
per fraction, no concomitant chemotherapy) (Figure 1B), who
presented with a grade 3 dermatitis at 46 Gy, which slowly healed
1 month after completing PT (Patient 2). Of note 10 out of 13
patients irradiated with concomitant chemotherapy presented
with dermatitis.
Only one patient with a head and neck tumor received
radiation to their primary and bilateral lymph nodes, whereas
all other patients received radiation to only their primary or
ipsilateral neck (e.g., salivary gland tumors). Figure 1C describes
a 79 year-old patient with non-operable cystic adenoid
carcinoma irradiated to 73.5 Gy (2.1 Gy per session) (Patient
3). This treatment was well tolerated with only grade 1 oral
mucositis and no dysgeusia.Frontiers in Oncology | www.frontiersin.org 4In pelvic and paraspinal tumors (n=16), PT was well tolerated
with no grade ≥ 3 gastrointestinal toxicities. Of note, there were
only 4 grade 1 gastrointestinal toxicities in this subgroup (3
diarrhea and 1 nausea).
Subacute Toxicities
Subacute toxicity, which occurred >2 months after completing
PT, are detailed in Table 3. Maximum subacute toxicity grade
was 0, 1, 2, 3, and 4 for 50 (39.4%), 39 (30.7%), 25 (19.7%), 12
(9.4%), and 1 (0.8%) patient(s), respectively. There were no grade
5 toxicities.
The most common subacute toxicity was dry eye (n=20, 18%
among cranial targets, no grade ≥3 toxicity), followed by seizures
(n=14, 12.6% among cranial targets). All patients with grade 3
seizures (n=6) were due to a new onset seizure with no prior
seizure history. Seizures were medically manageable for all
patients. Histology of patients who presented with a subacute
onset seizure was as follows: meningioma (n=7), low grade
glioma (n=4), ependymoma (n=1) and pituitary adenoma
(n=1). Of these, 8 presented with baseline seizures, 7 of which
were on antiepileptic drugs. Median delay to new onset or
worsening of seizure was 4.6 months (0.8–34.2) from the end
of PT. Of the pelvic and primary tumors, there was 1 grade 3
toxicity (colonic obstruction), in a previously irradiated pelvic
sarcoma, requiring hospitalization and resolved with medical
management. There was 1 grade 4 toxicity (left optic nerve
disorder), which occurred in a 72-year old women treated for
skull-based meningioma surrounding optic nerves bilaterally.
Left blindness occurred 1 year after PT with no evidence of
relapse. D1, D2 and Dmean to the left optic nerve were 53.7 Gy,
53.7 Gy, and 53.3 Gy, respectively.DISCUSSION
To our knowledge the current study is the first to report early
outcomes after high dose rate pulsed proton therapy. The cohort
primarily consists of cranial targets and benign disease. The
acute toxicities were as expected according to dosimetry,
especially for acute onset alopecia and dermatitis.
Unfortunately, the use of high dose rate pulsed PT did not
provide a significant “FLASH-like” radioprotective effect.
According to the FLASH electron therapy data, we should
have observed a much lower rate and intensity of acute side-
effects. In the preclinical setting, Favaudon et al. delivered 15 Gy
in a single FLASH dose (60 Gy/s) to the whole lungs without
inflammatory infiltration or extracellular matrix deposition after
62 days, whereas mice irradiated with classical dose rates (0.03/s)
presented with dense inflammatory infiltrate and extracellular
matrix deposition (7).
In our cohort, no patient received lung irradiation and cannot
comment on whether our “FLASH effect”might be dependent on
the nature of the irradiated tissue. However, Montay-Gruel et al.
reported that FLASH photon therapy could also have a
protective effect during brain irradiation (8, 10). Unfortunately,
we observed seizure rates of 3.6% (n=4 of 111 patients with
cranial irradiation) during PT and 12.6% (n=14 of 111 patientsTABLE 2 | Acute toxicities.
Grade 1 Grade 2 Grade 3 Grade 4 Total
Alopecia 40 0 0 0 40
Dermatitis radiation 24 14 1 0 39
Asthenia 20 6 0 0 26
Headache 20 3 1 0 24
Dry eye 18 6 0 0 24
Nausea 14 3 1 0 18
Sinusitis 8 7 0 0 15
Oral mucositis 9 1 2 0 12
Local pain 6 5 1 0 10
Dysgeusia 6 3 0 0 9
Dry mouth 5 2 0 0 7
Dizziness 5 0 0 0 5
Orbit edema 4 1 0 0 5
Anosmia 5 0 0 0 5
Seizure 1 2 1 0 4
Trismus 4 0 0 0 4
Local bleeding 4 0 0 0 4
Dyspnea 1 2 0 0 3
Diarrhea 3 0 0 0 3
Hearing impaired 2 0 0 0 2
Cranial nerve disorder 0 0 2 0 2
External otitis 2 0 0 0 2
Dysesthesia 1 1 0 0 2
Keratitis 1 0 0 0 1
Esophagitis 1 0 0 0 1
Palpitations 1 0 0 0 1
Cystitis 1 0 0 0 1
Vomiting 0 2 0 0 1January 2021 | Volume 10 | Article 613089
Doyen et al. High Dose Rate Proton Therapywith cranial irradiation) 2 months after PT. Most patients had a
previous history of epilepsy (n=8) and we observed six new
epilepsy diagnosis after PT. Weber et al. reported a similar rate of
post-radiation seizure after radiotherapy (21.5%) for atypical and
malignant meningioma (EORTC 22042–26042 phase II study)
(19). Lynam et al. observed a cumulative “delayed” seizure (afterFrontiers in Oncology | www.frontiersin.org 5treatment) rate of 33.8% (n=22 of 65 patients), especially in
patients with low grade glioma or meningioma, as seen in our
study (20).
We observed a very favourable toxicity profile for Patient 3
treated for non-operable cystic adenoid carcinoma of the parotid
(Figure 1C). Romesser et al. previously reported that ipsilateralFIGURE 1 | Dose distribution (A, left) and grade 1 alopecia (A, right) during proton therapy (PT) of patient with meningioma; dose distribution (B, Left) and grade 3
dermatitis (B, right) 1 month after PT for Merckel carcinoma of the vertex; dose distribution for cystic adenoid carcinoma of the right parotid (C, right, axial view;
C, left, coronal view).January 2021 | Volume 10 | Article 613089
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rate of acute toxicities when compared with photon therapy,
such as grade ≥ 2 dysgeusia (5.6% vs 65.2%, p<0.001) and grade ≥
2 mucositis (16.7% vs 52.2%, p=0.01) (21). The favorable toxicity
profile observed for Patient 3 is likely related to the Bragg Peak
advantage. In contrast, Patient 2 was treated for skin cancer of
the scalp vertex and presented with prolonged grade 3 toxicity.
This is consistent with the unfavorable skin tolerance seen in
previously described breast cancer cohorts treated with
conventional dose rate PT, with a rapid dose deposit on the
skin surface, which may be mitigated with proper dose
constraints (22).
Despite the high dose delivered (median of 65.1 Gy [50.4–
73.5]) and large irradiated volume (median of 437.4 ml [83.2–
2106]), there were limited gastrointestinal sequela for the 16
pelvic and paraspinal tumors, with only 1 grade 3 subacute
toxicity (digestive occlusion) reported 4 months after re-
irradiation for an 89 year old pelvic sarcoma (65.1 Gy in 31
fractions). This patient required hospitalization but the occlusion
quickly resolved with medical management alone. This is
consistent with the study by Schneider et al, who described the
conventional dose rate PT of 31 paraspinal/retroperitoneal
patients, with a mean total dose of 72.3 Gy in 1.8–2 GyFrontiers in Oncology | www.frontiersin.org 6fractions and planning target volume of 560.2 ml, observed no
acute or late grade ≥ 2 toxicities (23). Similar to the favorable
outcome in Patient 3, toxicity profile of the pelvic/paraspinal
cohort is likely due to the Bragg Peak advantage rather than a
FLASH-like effect.
Limitations of this study include: its retrospective nature, the
relative small number of patients, and short follow-up. With the
toxicities (e.g., dermatitis, alopecia, and seizures) observed in this
study,we can conclude that the use of high dose rate proton therapy
(around 10 Gy/s per spot) does not offer the expected FLASH-like
radioprotective effect. Itmay cause lower grade toxicities but proper
comparative studieswithconventionaldose ratePTareneeded.The
dose ratemight be dependent on the type of irradiation andmay be
more difficult to obtain with protons than it is for photons or
electrons. Larger dose per fractionmay also be needed. The FLASH
effect of protons was analyzed in the preclinical setting by
Buonanno et al, who evaluated various dose rate (0.05, 10, 20,
100, and 1000 Gy/s) effect on normal lung fibroblasts. They found
that the proton dose rate had little impact on acute effects, but
favorably influenced the 1-month expression of TGF-b (inverse
expression with dose rate) and 1-month cell senescence (lower
senescence with higher dose rate) (12). Therefore, the FLASH effect
of protons might be less pronounced than with other particles and
may require an even higher dose rate to be clinically significant. Of
note, most of this cohort consisted of head and neck tumors, where
toxicity benefit of high dose rate proton therapy may not be as
significant as other disease sites, such as abdominal or thoracic
treatment sites, whichwill require further analysis in future studies.
In conclusion, the present study describes the early outcomes
with use of high dose rate proton therapy (around 10 Gy/s).
Contrary to what was expected in preclinical studies, there was
no FLASH-like effect (no lack of toxicities). To identify a clinical
difference, when compared to the classical dose rate (<0.05 Gy/s),
may require larger cohorts, a match-paired retrospective study or
randomized prospective study, longer follow up, or possibly a
higher dose rate or dose per session.DATA AVAILABILITY STATEMENT
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